KI 0503
Alternative Names: KI0503Latest Information Update: 07 Oct 2021
At a glance
- Originator Kuhnil Pharmaceutical Company
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Joint disorders
Most Recent Events
- 07 Oct 2021 Discontinued - Phase-II for Joint disorders in South Korea (unspecified route) (Kuhnil Pharmaceutical Company pipeline)
- 20 Aug 2015 Phase-II development is ongoing in South Korea
- 01 Feb 2011 Phase-II clinical trials in Joint disorders in South Korea (unspecified route)